Preparation, characterization, in vitro and in vivo anti-tumor effect of thalidomide nanoparticles on lung cancer

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• TorreLASiegelRLJemalALung cancer statisticsAdv Exp Med Biol201689311926667336
   PubMed Web of Science ®Google Scholar
• ScharovskyOGMatarPRozadosVRImmunomodulation and antiangiogenesis in cancer therapy. From basic to clinical researchMedicina (B Aires)20127214757 Spanish [with English abstract]22257459
   PubMed Web of Science ®Google Scholar
• Nowak-SliwinskaPGriffioenAWAngiogenesis inhibitors in combinatorial approachesAngiogenesis201720218318428382510
   PubMed Web of Science ®Google Scholar
• ZhouSWangFFHsiehTCWuJMWuEThalidomide–a notorious sedative to a wonder anticancer drugCurr Med Chem201320334102410823931282
   PubMed Web of Science ®Google Scholar
• VargessonNThalidomide-induced teratogenesis: history and mechanismsBirth Defects Res C Embryo Today2015105214015626043938
   PubMed Web of Science ®Google Scholar
• WangDFuJShiYThe modulation of tumor vessel permeability by thalidomide and its impacts on different types of targeted drug delivery systems in a sarcoma mouse modelJ Control Release201623818619627422610
   PubMed Web of Science ®Google Scholar
• VargessonNThalidomide embryopathy: an enigmatic challengeISRN Dev Biol201320133118
   Google Scholar
• HuangYTChengCCChiuTHLaiPCTherapeutic potential of thalidomide for gemcitabine-resistant bladder cancerInt J Oncol20154751711172426398114
   PubMed Web of Science ®Google Scholar
• HoangTDahlbergSESchillerJHRandomized phase III study of thoracic radiation in combination with paclitaxel and car-boplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 studyJ Clin Oncol201230661662222271472
   PubMed Web of Science ®Google Scholar
• QiaoZYuanJShenJEffect of thalidomide in combination with gemcitabine on human pancreatic carcinoma SW-1990 cell lines in vitro and in vivoOncol Lett2015952353236026137070
   PubMed Web of Science ®Google Scholar
• CaoDDXuHLLiuLThalidomide combined with transcatheter arterial chemoembolization for primary hepatocellular carcinoma: a systematic review and meta-analysisOncotarget2017827449764499328402958
   PubMedGoogle Scholar
• HungriaVTCrusoéEQMaiolinoAPhase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligibleAnn Hematol201695227127826518211
   PubMed Web of Science ®Google Scholar
• GaoMKongYWangHThalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trialsTumour Biol2016378110811109826906553
   PubMedGoogle Scholar
• Ozanic BulicSFassihiHMellerioJEMcGrathJAAthertonDJThalidomide in the management of epidermolysis bullosa pruriginosaBr J Dermatol200515261332133415949003
   PubMed Web of Science ®Google Scholar
• FuSXiaJWuJFunctional chitosan nanoparticles in cancer treatmentJ Biomed Nanotechnol2016121585160329341581
   PubMed Web of Science ®Google Scholar
• XuHHouZZhangHAn efficient Trojan delivery of tetrandrine by poly(N-vinylpyrrolidone)-block-poly(ε-caprolactone) (PVP-b-PCL) nanoparticles shows enhanced apoptotic induction of lung cancer cells and inhibition of its migration and invasionInt J Nanomedicine20149123124224403829
   PubMedGoogle Scholar
• DinarvandRSepehriNManoochehriSRouhaniHAtyabiFPolylactide-co-glycolide nanoparticles for controlled delivery of anticancer agentsInt J Nanomedicine2011687789521720501
   PubMed Web of Science ®Google Scholar
• DerakhshandehKSoheiliMDadashzadehSSaghiriRPreparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patientsInt J Nanomedicine20105146347120957168
   PubMedGoogle Scholar
• ChenHGuYHuYComparison of two polymeric carrier formulations for controlled release of hydrophilic and hydrophobic drugsJ Mater Sci Mater Med200819265165817619980
   PubMed Web of Science ®Google Scholar
• JinHHemingwayMGuptaRBXiaFZhaoYPreparation of thalidomide nano-flakes by supercritical antisolvent with enhanced mass transferParticuology20121011723
   Web of Science ®Google Scholar
• SuksuwanALomlimLRungrotmongkolTNakphengTDickertFLSuedeeRThe composite nanomaterials containing (R)-thalidomide-molecularly imprinted polymers as a recognition system for enantioselective-controlled release and targeted drug deliveryJ Appl Polym Sci2015132181436814373
   Web of Science ®Google Scholar
• YuYXuSYouHIn vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinomaDrug Deliv2017241758228155566
   PubMed Web of Science ®Google Scholar
• ZhangHLiXDingJDelivery of ursolic acid (UA) in polymeric nanoparticles effectively promotes the apoptosis of gastric cancer cells through enhanced inhibition of cyclooxygenase 2 (COX-2)Int J Pharm20134411–226126823194884
   PubMedGoogle Scholar
• TanLWMaBYZhaoQToxicity evaluation and anti-tumor study of docetaxel loaded mpeg-polyester micelles for breast cancer therapyJ Biomed Nanotechnol201713439340829384603
   PubMed Web of Science ®Google Scholar
• JungBShimMKParkMJHydrophobically modified polysaccharide-based on polysialic acid nanoparticles as carriers for anticancer drugsInt J Pharm20175201–211111828179099
   PubMedGoogle Scholar
• DiabRHamoudehMBoyronOElaissariAFessiHMicroen-capsulation of cytarabine using poly(ethylene glycol)-poly(epsilon-caprolactone) diblock copolymers as surfactant agentsDrug Dev Ind Pharm201036445646919877831
   PubMed Web of Science ®Google Scholar
• El-AaragBKasaiTMasudaJAgwaHZahranMSenoMAnticancer effects of novel thalidomide analogs in A549 cells through inhibition of vascular endothelial growth factor and matrix metalloproteinase-2Biomed Pharmacother20178554955527889230
   PubMed Web of Science ®Google Scholar
• ChangLGongFCaiHLiZCuiYCombined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancerOncol Lett20161121242125026893726
   PubMed Web of Science ®Google Scholar
• CiprianiPSmithCYCharacterization of thalidomide using Raman spectroscopySpectrochim Acta A Mol Biomol Spectrosc200869233333717521959
   PubMed Web of Science ®Google Scholar
• SherbetGVTherapeutic potential of thalidomide and its analogues in the treatment of cancerAnticancer Res201535115767577226503997
   PubMed Web of Science ®Google Scholar
• CalabreseLResztakKThalidomide revisited: pharmacology and clinical applicationsExpert Opin Investig Drugs199871220432060
   PubMedGoogle Scholar
• XiongWPengLChenHLiQSurface modification of MPEG-b-PCL-based nanoparticles via oxidative self-polymerization of dopamine for malignant melanoma therapyInt J Nanomedicine2015102985299625945046
   PubMed Web of Science ®Google Scholar
• LiuBHanLLiuJHanSChenZJiangLCo-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancerInt J Nanomedicine20171295596828203075
   PubMed Web of Science ®Google Scholar
• WeiMXuYZouQHepatocellular carcinoma targeting effect of pegylated liposomes modified with lactoferrinEur J Pharm Sci201246313114122369856
   PubMed Web of Science ®Google Scholar
• RafieiPHaddadiADocetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profileInt J Nanomedicine20171293594728184163
   PubMed Web of Science ®Google Scholar
• VoonSHTiewSXKueCSChitosan-coated poly (lactic-co-glycolic acid)-diiodinated boron-dipyrromethene nanoparticles improve tumor selectivity and stealth properties in photodynamic cancer therapyJ Biomed Nanotechnol20161271431145229336539
   PubMed Web of Science ®Google Scholar
• LiuQLiRZhuZEnhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticlesInt J Pharm20124301–235035822525076
   PubMed Web of Science ®Google Scholar
• LiuLSunLWuQCurcumin loaded polymeric micelles inhibit breast tumor growth and spontaneous pulmonary metastasisInt J Pharm20134431–217518223287774
   PubMedGoogle Scholar
• TaromiSKayserGvon ElverfeldtDAn orthotopic mouse model of small cell lung cancer reflects the clinical course in patientsClin Exp Metastasis201633765166027380917
   PubMed Web of Science ®Google Scholar
• GuoJCaiJZhangYZhuYYangPWangZEstablishment of two ovarian cancer orthotopic xenograft mouse models for in vivo imaging: a comparative studyInt J Oncol20175141199120828902355
   PubMed Web of Science ®Google Scholar
• WangXShenYLiSImportance of the interaction between immune cells and tumor vasculature mediated by thalidomide in cancer treatment (review)Int J Mol Med20163841021102927599781
   PubMed Web of Science ®Google Scholar
• MarriottJBClarkeIACzajkaAA novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsCancer Res200363359359912566301
   PubMed Web of Science ®Google Scholar
• KellerMSollbergerGBeerHDThalidomide inhibits activation of caspase-1J Immunol200918395593559919843943
   PubMed Web of Science ®Google Scholar
• DredgeKDalgleishAGMarriottJBAngiogenesis inhibitors in cancer therapyCurr Opin Investig Drugs200346667674
   PubMedGoogle Scholar
• PiuraBMedinaLRabinovichADyominVHuleihelMThalidomide distinctly affected TNF-α, IL-6 and MMP secretion by an ovarian cancer cell line (SKOV-3) and primary ovarian cancer cellsEur Cytokine Netw201324312212924284039
   PubMed Web of Science ®Google Scholar